Mangalam Drugs & Organics Ltd
Company Profile
Business description
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
Contact
P. D'Mello Road
Rupam Building, 3rd Floor, No. 239
Near General Post Office
MumbaiMH400001
INDT: +91 2222616200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
480
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
stocks
New production imminent for undervalued ASX gas play
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,324.60 | 40.80 | 0.44% |
CAC 40 | 8,189.52 | 0.93 | 0.01% |
DAX 40 | 23,830.99 | 441.20 | -1.82% |
Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
FTSE 100 | 9,348.01 | 88.08 | -0.93% |
HKSE | 25,805.29 | 558.19 | 2.21% |
NASDAQ | 22,679.97 | 117.44 | 0.52% |
Nikkei 225 | 48,995.17 | 1,413.02 | 2.97% |
NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
S&P 500 | 6,664.01 | 34.94 | 0.53% |
S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
SSE Composite Index | 3,857.41 | 17.66 | 0.46% |